More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.89B
EPS
0.68
P/E ratio
15
Price to sales
4.79
Dividend yield
--
Beta
0.719378
Previous close
$8.06
Today's open
$8.09
Day's range
$8.02 - $8.30
52 week range
$7.21 - $22.37
show more
CEO
Adam S. Grossman
Employees
647
Headquarters
Ramsey, NJ
Exchange
NASDAQ Global Market
Shares outstanding
232324283
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
ADMA Biologics Investigation: ADMA Biologics (ADMA) Investigated for Alleged Channel Stuffing – Contact BFA Law if You Suffered Losses
NEW YORK, June 10, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit.
GlobeNewsWire • 8 hours ago

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA
New York, New York--(Newsfile Corp. - June 7, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA) resulting from allegations that ADMA Biologics may have issued materially misleading business information to the investing public. SO WHAT: If you purchased ADMA Biologics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Newsfile Corp • Jun 7, 2026

Adma Biologics (ADMA) Down 5.8% Since Last Earnings Report: Can It Rebound?
Adma Biologics (ADMA) reported earnings 30 days ago. What's next for the stock?
Zacks Investment Research • Jun 5, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
PRNewsWire • Jun 4, 2026

ADMA Legal Claims: ADMA Biologics may have Misrepresented its Revenue Sources to Investors – Contact BFA Law about its Pending Securities Fraud Investigation
NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit.
GlobeNewsWire • Jun 3, 2026

New Strong Sell Stocks for June 3rd
AOS, ADMA and AMTB have been added to the Zacks Rank #5 (Strong Sell) List on June 3rd, 2026.
Zacks Investment Research • Jun 3, 2026

ADMA Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA) resulting from allegations that ADMA Biologics may have issued materially misleading business information to the investing public.
GlobeNewsWire • Jun 2, 2026

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA
New York, New York--(Newsfile Corp. - June 1, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA) resulting from allegations that ADMA Biologics may have issued materially misleading business information to the investing public. SO WHAT: If you purchased ADMA Biologics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Newsfile Corp • Jun 2, 2026

ADMA Biologics: Longstanding Bull Hits The Reset Button After Murky Q1 Earnings
ADMA Biologics (ADMA) faces IVIG market headwinds, flat Q1 revenue, and reduced 2026 guidance, leading to a >50% YTD share price decline. ASCENIV's differentiated profile drove 28% YoY revenue growth and record utilization, partially offsetting BIVIGAM's 54% decline amid IVIG pricing pressure. Gross margin expanded to 71%, adjusted EBITDA rose 24% YoY, and strong cash generation supports resilience despite market disruption.
Seeking Alpha • May 29, 2026

$ADMA Securities News: ADMA Biologics Investigated for Securities Fraud Over Channel Stuffing Allegations – Investors with Losses Notified to Contact BFA Law
NEW YORK, May 29, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit.
GlobeNewsWire • May 29, 2026

¹ Disclosures

Open an M1 investment account to buy and sell ADMA Biologics Inc commission-free¹. Build wealth for the long term using automated trading and transfers.